Premium
Retrospective analysis of the clinicopathologic and prognostic characteristics of stage I placental site trophoblastic tumor in China
Author(s) -
Zheng Yunxi,
Bao Lingjie,
Ning Yan,
Lu Xin,
Hua Keqin,
Yi Xiaofang
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2014.10.027
Subject(s) - medicine , placental site trophoblastic tumor , retrospective cohort study , univariate analysis , stage (stratigraphy) , gynecology , survival analysis , oncology , mitotic index , pregnancy , obstetrics , multivariate analysis , fetus , paleontology , placenta , biology , microbiology and biotechnology , genetics , mitosis
Abstract Objective To investigate clinicopathologic features and identify prognostic factors of placental site trophoblastic tumor (PSTT). Methods In a retrospective study, data were analyzed from patients with stage I PSTT treated at a tertiary hospital in Shanghai, China, from January 2007 to May 2013. Univariate log‐rank tests were used to examine the association between clinicopathologic characteristics and overall survival and disease‐free survival (DFS). Results In total, seven patients had stage I PSTT. Mean age was 31.6 years (range 22–42). Four patients had term delivery as the outcome of their antecedent pregnancy. Six had a β‐human chorionic gonadotropin (β‐hCG) serum concentration of less than 10 000 mIU/mL. Among five patients who underwent hysterectomy combined with chemotherapy, one had recurrent disease. One patient received fertility‐preserving therapy and achieved complete remission. The mean 5‐year overall survival and DFS were 100% and 86%, respectively. Maximum β‐HCG concentration of at least 10 000 mIU/mL and a mitotic index of more than 5 mitotic counts per 10 high‐power fields were associated with disease recurrence (both P = 0.014). Conclusion Pretreatment β‐hCG concentration and mitotic index might be predictors of recurrence among patients with PSTT. Fertility‐preserving therapy might be practical in some patients.